Printer Friendly

Cystic fibrosis marker.

A first step toward identifying the gene responsible for cystic fibrosis was reported last week by two biotechnology companies. The work is expected to lead to a screening test for carriers of the disease and eventually to new treatments.

Cystic fibrosis is the most common lethal genetic disease in the United States. Approximately one in every 2,000 U.S. Caucasian babies is born with the disease; most do not survive beyond their early twenties.

Two genetic markers for cystic fibrosis were described in Salt Lake City by independent research groups at the meeting of the American Society for Human Genetics. A genetic market is a segment of DNA identified by scientists that is located near an unidentified gene of interest. By following inheritance of the market within a family, scientists can determine who is likely to inherit the gene. The marker also indicates where within the chromosomes a gene is located.

One genetic marker for cystic fibrosis is located on chromosome 21, reports Integrated Genetics of Framingham, Mass. In collaboration with scientists at the University of Rochester and Yale University, company researchers determined there is a 94 percent probability that the marker and cystic fibrosis gene will be inherited together.

Another genetic marker for cystic fibrosis was reported by scientists at Collaborative Research, Inc., of Lexington, Mass., and at the Hospital for Sick Children in Toronto. The chromosomal location of this genetic marker is still being determined, but it appears to be inherited with the cystic fibrosis gene 85 percent of the time.

The two new cystic fibrosis markers appear to be linked to different genes, says Thomas O. Oesterling of Collaborative Research. He suggests that there are two genes that cause the disease in different families, and that the marker discovered by Collaborative Research is linked to the major gene. The companies are planning an exchange of markers to test on different families.
COPYRIGHT 1985 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1985, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Author:Miller, Julie Ann
Publication:Science News
Date:Oct 19, 1985
Words:315
Previous Article:Hyperbaric oxygen bounces back; after years in the shadows, high-dose, high-pressure oxygen administration is making a comeback as a legitimate...
Next Article:FDA okays heart savers.
Topics:


Related Articles
Inner workings of cystic fibrosis.
Closing in on the cystic fibrosis gene.
Blood cells yield cystic fibrosis clues.
Cystic fibrosis gene and protein identified.
Diuretic slows cystic fibrosis damage.
CF: maxi-mutations make mini-diseases.
Cystic fibrosis gene: too many mutants.
Gene, biochemical fixes sought for CF.
What good is the cystic fibrosis gene?
Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. (Research).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters